RS PHARMA
ActiveThe computed 12-month bankruptcy probability of RS PHARMA is 3.1% (moderate). The 2024 annual accounts show equity of €112k and a net result of €69k. Its solvency ranks better than 88% of 15869 sector peers (fiscal year 2024). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2024
81
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2023
Profitability100=
Solvency100▲+9
Growth78
Track record94
Bankruptcy probability, 12 months
3.1%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €9k at 30 days acceptable
Liquidity ample (current ratio 7.02 against 2.92 in 2023; short-term debt: 13.8% and cash: 75.2% of total assets), and 13.8% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Sector 46
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
86.2%
Return on assets
53.3%
Age of the figures
21 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 06-08-2025, 6 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 2 filingsDeviation from the deadline
2025
not confirmed
2024
6 d late
2023
28 d late
← before the deadline
after the deadline →
Financials · fiscal year 2024, micro schema
Equity
€112k▲ 162%
2023 · €43k
2023: €43k
2023 → 2024
Total assets
€130k▲ 102%
2023 · €64k
2023: €64k
2023 → 2024
Net result
€69k▲ 83.4%
2023 · €38k
2023: €38k
2023 → 2024
Working capital
€107k▲ 159%
2023 · €42k
2023: €42k
2023 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20232024Trend
Equity€43k-€112k▲ 162%
Operating result€50k-€94k▲ 87.2%
Net result€38k-€69k▲ 83.4%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result rises in 2024; 2024 is 87% above 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €130k
Fixed assets
€5k▲ 280%
Current assets
€125k▲ 98.3%
Equity and liabilities €130k
Equity
€112k▲ 162%
Debt
€18k▼ 17.4%
The debt ratio falls from 33.6% to 13.8%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€96k▲
2023 · €50k
Cash flow
€70k▲
2023 · €38k
Solvency
86.2%▲
2023 · 66.4%
Current ratio
7.02▲
2023 · 2.92
Quick ratio
7.02▲
2023 · 2.92
Debt / equity
0.16▼
2023 · 0.51
ROE
61.8%▼
2023 · 88.3%
ROA
53.3%▼
2023 · 58.6%
Interest coverage
935.21
Debt
€18k▼
2023 · €22k
Debt ≤ 1 year
€18k▼
2023 · €22k
Income taxes
€25k▲
2023 · €13k
Staff costs
€9k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2024 against 2023
Balance sheet
Code20232024
Assets
Total assets20/58€64k€130k▲
Fixed assets21/28€1k€5k▲
Tangible fixed assets22/27€1k€5k▲
Furniture and vehicles24€1k€5k▲
Current assets29/58€63k€125k▲
Amounts receivable within one year40/41€10k€25k▲
Trade receivables40€10k€25k▲
Cash at bank and in hand54/58€53k€98k▲
Deferred charges and accrued income490/1€72€2k▲
Equity and liabilities
Total equity and liabilities10/49€64k€130k▲
Equity10/15€43k€112k▲
Contributions10/11€5k€5k=
Profit (loss) carried forward14€38k€107k▲
Amounts payable17/49€22k€18k▼
Amounts payable within one year42/48€22k€18k▼
Trade debts44-€2k
Suppliers440/4-€2k
Taxes, remuneration and social security45€21k€11k▼
Taxes450/3€21k€10k▼
Remuneration and social security454/9-€1k
Other amounts payable47/48€131€4k▲
Income statement
Code20232024
Remuneration, social security and pensions62-€9k
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€16€1k▲
Other operating charges640/8-€1k
Gross operating margin9900€50k€106k▲
Operating profit (loss)9901€50k€94k▲
Financial charges65/66B-€102
Recurring financial charges65-€102
Profit (loss) for the period before taxes9903€50k€94k▲
Income taxes67/77€13k€25k▲
Profit (loss) for the period9904€38k€69k▲
Profit (loss) for the period to be appropriated9905€38k€69k▲
Appropriation of the result
Profit (loss) to be appropriated9906€38k€107k▲
Profit (loss) brought forward from the previous period14P-€38k
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
06-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 6 days late
2024
31-12
Financial
Liquidity doublescurrent ratio 7.02
Current ratio from 2.92 to 7.02; short-term debt falls from €22k to €18k.
31-12
Financial
Equity above €100kEq €112k ▲162%
2 profitable years in a row build equity to €112k.
28-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 28 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Sint-Agatha-Berchem · 1 establishment unit since 2023
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Groot-Bijgaardenstraat 1071082 Sint-Agatha-BerchemGround area
327 m²
Building footprint
60 m²
Volume, LiDAR
601 m³
Parcel 21342B0045/00X003, Brussels · tallest building 12.2 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
RS PHARMA
since 20232.344.596.995
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21342B0045/00X003 | Brussels | 327 m² | 1 · 60 m² | 12.2 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
NETTECO
BE 0740.978.347
Enghien · Eq €111k
BAGICA
BE 0421.803.906
Ieper · Eq €113k
MEDIA MARKT GOSSELIES/CHARLEROI
BE 0869.773.561
Charleroi · Eq €110k
D.K.R. Commercial
BE 0803.365.282
Kortrijk · Eq €114k
PARTNERS & ZONEN
BE 0817.621.413
Antwerpen · Eq €109k
Of 1,745 companies in sector 46150 we hold annual accounts for 757. 589 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded18-04-2023
Fiscal year end31-12
Activities, NACEBEL
46150Agents in the wholesale of furniture, household goods and hardware
47730Retail sale of pharmaceutical products
46130Agents in the wholesale of timber and building materials
Sources
Crossroads Bank for EnterprisesNational Bank · 2 filingsAddress and cadastre registers
Data from official sources, last processed on 17-09-2026. Scores and ratios are computed by Checked and are not a credit decision.